Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: BUY (auto-tracking)
5.92% $4.83
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 6.43 mill |
EPS: | -13.19 |
P/E: | -0.370 |
Earnings Date: | Mar 28, 2024 |
SharesOutstanding: | 1.332 mill |
Avg Daily Volume: | 0.118 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.370 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.370 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.19 - 5.47 ( +/- 13.25%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-20 | Huntsman Ronald Kirk | Buy | 14 000 | Common Stock |
2023-06-16 | Huntsman Ronald Kirk | Buy | 5 000 | Common Stock |
2023-06-16 | Huntsman Ronald Kirk | Buy | 10 000 | Common Stock |
2023-06-15 | Huntsman Ronald Kirk | Buy | 21 | Common Stock |
2023-06-14 | Huntsman Ronald Kirk | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 44 transactions |
Buy: 1 747 856 | Sell: 433 336 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.83 (5.92% ) |
Volume | 0.0592 mill |
Avg. Vol. | 0.118 mill |
% of Avg. Vol | 50.33 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:18 | buy | $5.20 | N/A | Active |
---|
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.